Atlas Trials

Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma

Clinical trial NCT07619937 · COMPLETED

Trial details

NCT number
NCT07619937
Sponsor
The First Affiliated Hospital of Zhengzhou University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Cholangiocarcinoma
Start date
2022-07-22
Primary completion
2025-09-30
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.